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Summary
Background The Edinburgh randomised trial of breast-
cancer screening recruited women aged 45–64 years from
1978 to 1981 (cohort 1), and those aged 45–49 years
during 1982–85 (cohorts 2 and 3). Results based on 14
years of follow-up and 270 000 woman-years of observation
are reported. 
Methods Breast-cancer mortality rates in the intervention
group (28 628 women offered screening) were compared
with those in the control group (26 026) with adjustment for
socioeconomic status (SES) of general medical practices.
Rate ratios were derived by means of logistic regression for
the total trial population and for women first offered
screening while younger than 50 years. Analyses were by
intention to treat.
Findings Initial unadjusted results showed a difference of
just 13% in breast-cancer mortality rates between the
intervention and control groups (156 deaths [5·18 per
10000] vs 167 [6·04 per 10000]; rate ratio 0·87 [95% CI
0·70–1·06]), but the results were influenced by differences
in SES by trial group. After adjustment for SES, the rate ratio
was 0·79 (95% CI 0·60–1·02). When deaths after diagnosis
more than 3 years after the end of the study were censored
the rate ratio became 0·71 (0·53–0·95). There was no
evidence of heterogeneity by age at entry and no evidence
that younger entrants had smaller or delayed benefit (rate
ratio 0·70 [0·41–1·20]). No breast-cancer mortality benefit
was observed for women whose breast cancers were
diagnosed when they were younger than 50 years. Other-
cause mortality rates did not differ by trial group when
adjusted for SES.
Interpretation Our findings confirm results from randomised
trials in Sweden and the USA that screening for breast
cancer lowers breast-cancer mortality. Similar results are
reported by the UK geographical comparison, UK Trial of
Early Detection of Breast Cancer. The results for younger
women suggest benefit from introduction of screening before
50 years of age.
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I n t r o d u c t i o n
The Edinburgh randomised trial of breast-cancer
screening was started in 1978.1 Between 1978 and 1981,
the trial recruited 44 288 women aged 45–64 years of
age from 87 general practices in Edinburgh to form the
initial cohort. Subsequently, further eligible women who
became patients of these practices and existing patients
who reached 45 years of age were recruited in two
further cohorts, 4867 in 1982–83 (cohort 2) and 5499 in
1984–85 (cohort 3).2 Participating practices were
randomly assigned to intervention and control groups,
women taking their status from their general medical
practice at their time of entry. Women in the
intervention group were invited to participate in a
screening programme, which included clinical
examination every year and two-view mammography
every 2 years. Control-group women received only
normal medical care. The prospectively defined
hypothesis was that breast-cancer mortality would be
lower in the intervention group than in the control group
after 7 years and longer periods of follow-up. At that
time, there was no reason to believe that the effect might
differ by age of entry to the trial and no subgroup
analyses were planned. Subsequent evidence from other
randomised controlled trials of mammographic
screening have placed importance on two age-groups
(<50 years, 50 years at entry).
There have been two reports2 , 3 of mortality from
breast-cancer relating to experience of women in the
initial cohort followed up for 7 and 10 years,
respectively. The second report also included the
l a t e r cohorts over a shorter follow-up period. For both
these follow-up periods, we report that breast-cancer
mortality was 17–18% in the screening group; these
differences were not significant. The 10-year analysis
reported that breast-cancer mortality was 22% lower in
the screening group for younger women aged 45–59
years at entry.
As a result of the cluster randomisation, there was bias
between the two groups, women in the control group
having higher all-cause mortality rates and lower
socioeconomic status (SES) than those randomly
assigned to intervention.4 Attempts to adjust for these
differences by quantifying SES in samples from each
practice were unsuccessful.2 , 3 An improved method of
quantifying SES has now been developed, which we
believe adjusts for this bias.5 We include in this report
the effect of this adjustment on breast-cancer mortality
rates after 14 years and separately consider the effect of
screening for younger women.
With longer periods of follow-up, the inclusion of
women whose diagnosis could not have been influenced
by screening becomes difficult. The consequences of
14 years of follow-up from the Edinburgh randomised trial of
breast-cancer screening
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different policies on censoring of deaths by their date of
diagnosis were considered in the Swedish overview
a n a l y s i s6 and the 14-year report of the Health Insurance
Plan (HIP) trial7 and are now considered for the first
time for the Edinburgh randomised trial. The HIP
i n v e s t i g a t o r s7 were the first to note that for entrants
younger than 50 years to the intervention group benefit
was restricted to women whose breast cancers were
diagnosed when they were in their fifties. Indeed, breast-
cancer mortality for women whose breast cancers were
diagnosed when they were younger than 50 years was
higher in the intervention than in the control group. A
corresponding analysis is now done for the Edinburgh
trial. Women in the intervention group of the Edinburgh
trial formed the Edinburgh component of the UK Trial
of Early Detection of Breast Cancer (TEDBC).8 T h e
latest results of TEDBC are also reported in this issue.9
M e t h o d s
Study participants and design
The geographical base for this trial was 87 general medical
practices within the city of Edinburgh.1 The only practices not
included were those that had participated in a pilot study or
refused to take part. Every woman aged 45–64 years registered
at one of these practices and without a previous diagnosis of
breast cancer was eligible for entry to the trial. Practices were
individually randomised after stratification by number of
partners (to balance the numbers in the two groups) and
entered sequentially between 1978 and 1981. All women aged
45–64 years from each practice were entered as the practice was
recruited (with cluster randomisation of women) to form an
initial cohort (cohort 1). During two 2-year periods (1982–83
and 1984–85), newly eligible women registered with
participating practices were also recruited to form cohorts 2 and
3. We included only women aged 45–49 years at entry in these
two cohorts. Older entrants to these cohorts were mainly
women who had moved to Edinburgh and were not
representative of the population. The only exclusion criterion
applied at trial onset was a previous diagnosis of breast cancer,
but this was normally ascertained after randomisation (figure 1 ) .
Informed consent was obtained for the screening process, but
not for trial entry. The trial was approved by the Lothian
Research Ethics Committee. The primary outcome measure
was the rate ratio of breast-cancer mortality rates in the two
groups; the trial was designed to have 80% statistical power to
detect a 30% lower mortality rate in the intervention group
after 7 years of follow-up (rate ratio 0·70), by a one-sided
t e s t .1 Power calculations ignored the cluster randomisation.
The study continued until 1988, with women in the
intervention group offered a maximum of four mammographic
screenings every 2 years for cohort 1, three screenings for
cohort 2, and two screenings for cohort 3. During the study
period these women were also offered clinical breast
examinations once a year. With the start of service screening in
Edinburgh in June, 1988, all trial women younger than 65 years
were eligible to be screened. Those who had participated in
regular screening during the trial were invited for their first
service screening 3 years after their last trial screening. Controls
were invited for their first service screening at the
corresponding time: year 10 from entry for the initial cohort,
and years 8 and 6 for cohorts 2 and 3, respectively.
The records of all women in the trial were flagged by the
General Registry Office in Edinburgh in 1985. This standard
UK procedure allows follow-up information on cancer
incidence, breast-cancer mortality, and other-cause mortality to
be sent to the trial administrators wherever individual
participants are living. This report is restricted to the 98% of
women whose records were successfully flagged. Failure of
flagging is therefore a second exclusion criterion; most of the
women whose records were not flagged had died or left
Edinburgh before the trial began, although their records
remained on their general practice list.1
Data analysis
Mortality statistics were based on death certification accessed
through the flagging process. Breast-cancer deaths are those in
which breast cancer was mentioned on the death certificate as
the underlying cause, according to WHO rules.1 0 All such
deaths were checked against the trial database and, if necessary,
additional sources. They were included only after confirmation
that the date at which breast cancer was diagnosed was later
than that of randomisation. All deaths in which breast cancer
was not the underlying cause were recorded as other-cause
mortality. The follow-up period is 14 years for cohort 1, 12
years for cohort 2, and 10 years for cohort 3, from date of
randomisation. To counteract the effect of the inclusion of
deaths from breast cancer that could not have been influenced
by screening, results are presented not only for all deaths during
follow-up, but also with death censored if diagnosis occurred
after a specified date (1987, 1989, 1991) and if the diagnosis
occurred after a specified number of years in the study.
Additional analyses censored deaths after diagnoses before or
after age 50 years to allow comparisons with results from the
HIP trial.7
Breast-cancer and other-cause mortality rates were calculated
as rates per 10 000 woman-years at risk for the two groups in
the trial, and the risk ratio calculated with a modified logistic
regression procedure, as in previous studies,2 , 3 i n c o r p o r a t i n g
adjustment for extrabinomial variation by the method of
W i l l i a m s1 1 to respect the cluster randomisation. These analyses
were done in SAS Proc Logistic version 6.12 and stratified by
age at randomisation (45–49 years, 50–54 years, 55–59 years,
60–64 years). When the later cohorts were included further
stratification by cohort was added. Age-specific results were
derived from fitting of interaction terms for age with trial group,
but all women were included in the modelling process.
Cumulative mortality curves were expressed as rates per 10 0 0 0
women entered, but were adjusted to take account of woman-
years at risk. Our method of analysis differs somewhat from that
used for TEDBC; that trial used Poisson rather than logistic
regression, but we used the TEDBC method9 to confirm that the
differences in statistical methods do not explain the divergence
between their results and ours. Analyses are by intention to treat.
The trial database, during the study phase, held and still
holds the best (most accurate) address for each woman. These
addresses did not include postal codes. When we noted in 1983
that there was an imbalance in all-cause mortality between the
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Figure 1: Trial profile
two trial groups, addresses of 20% of women from each general
practice were given postal codes manually and 1981 census
data derived from these postal codes were used to allocate an
SES score to each practice.4 From this score, practices were
classified into three groups (high, medium, and low SES). This
classification system (SES-1) has the strength that it was
derived before any inspection of breast-cancer mortality but it
did not succeed in eliminating the difference in other-cause
m o r t a l i t y .2 , 3 Postal codes have now been allocated by computer
to the addresses of almost all women in the trial, allowing
retrieval of the Carstairs index of deprivation! 2 for the area of
residence of each woman. The mean value of Carstairs index
for general practices was used to derive a continuous variable
(Carstairs score) for general practices.5 The Carstairs score was
used to assign practices into three groups (system SES-2) as
b e f o r e .
All analyses were repeated with adjustment for each of SES-1
(as used previously), and SES-2 and Carstairs score in the
logistic regression model. In these adjusted analysis, we fitted
terms for SES using the total trial population, even to report
age-specific results. This approach assumes that the effect of
SES is independent of age entry to the trial. That assumption
has been verified; the interaction between SES and age at entry
did not approach conventional levels of significance.
R e s u l t s
Table 1 shows the number of women and woman-years
at risk in cohort 1 by age at entry and for those aged
45–49 years at entry in cohorts 2 and 3. Women in
cohorts 2 and 3 were generally younger at age of entry
than those in the 45–49-year age-group in cohort 1
(mean age cohort 1, 47·4 years; cohort 2, 46·1 years;
cohort 3, 45·8 years). When the cohorts are combined,
they allow a direct comparison of 22 746 women who
were younger than 50 years at entry (11 4 7 9
intervention and 10 267 control).
Women in the intervention group were offered 
an initial screening and up to six further screenings
(three mammographic) for the initial cohort, four (with
two mammographic) for cohort 2, and two (one
mammographic) for cohort 3. 61·3% of women in the
intervention group accepted the first invitation to
screening, but attendance rates fell with time and were
just over 50% during the final year of the study.
Attendance at screening for women in the intervention
group was strongly associated with SES (table 2).
Younger women (45–49 years at entry) began trial
screening under age 50 years but many continued to
receive trial screening after 50 years. Of all trial
screenings for these younger women 46·0% for the
initial cohort, 79·0% for cohort 2, and 97·5% for cohort
3 were done when they were under 50 years. Little
screening was available in Edinburgh during the study
period (1978–88) and we believe that very few women in
the control group arranged screening for themselves,
although we have no way of confirming this assumption.
In cohort 1 followed up for 14 years there were 323
deaths in which breast cancer was the underlying cause.
Analysis without adjustment for SES or with the
previous method of adjustment (SES-1) showed
differences of 13–16% between the intervention groups,
which were not significant (table 3). Analysis of the
unadjusted data by the TEDBC method gave almost
identical point estimates.
However, adjustment by SES-2, in three categories or
as a continuous variable (Carstairs score), gave point
estimates for differences in breast-cancer mortality rates
of 21–22%, which are of borderline significance
(p=0·055 and 0·05, respectively). There was no
significant interaction between age-group at entry and
trial group (p=0·6), but we show results by age of entry
within cohort 1 in table 3. All 95% CI are wide, but
point estimates for all groups, except those of 50–54
years, are similar to the overall results; the difference in
breast-cancer mortality between intervention and control
groups for the youngest women (45–49 years) in the
initial cohort was 30%.
When the late entrants (cohorts 2 and 3) were
included in the 45–49-year age-group, the point estimate
of the difference in breast-cancer mortality rates was
25%. Although the 95% CI was narrower, this
difference in mortality is not significant. Cumulative
breast-cancer mortality rates for the initial cohort at all
ages and for women in all three cohorts entered at ages
45–49 years by trial group are shown in figure 2.
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Age at entry Intervention group Control group
(years)
Number of Woman- Number of Woman-
women years of women years of
follow-up follow-up
Cohort 1
45–49 5777 78 761 5594 75 726
50–54 5878 78 838 5168 68 316
55–59 6109 79 500 5749 73 507
60–64 5162 64 055 4831 58 814
45–64 22 926 301 155 21 342 276 363
Cohort 2
45–49 2495 29 414 2381 28 029
Cohort 3
45–49 3207 31 693 2292 22 658
Table 1: Trial population and woman-years of follow-up
SES-2 Number of women from intervention group Number of first-time 
Attending first screen Attending last screen
attenders attending
last screen
High 8212 (79%) 5747 (55%) 5747 (70%)
Medium 3961 (73%) 2632 (49%) 2632 (66%)
Low 2507 (70%) 1515 (42%) 1515 (60%)
Table 2: Proportions of women attending for screening
according to SES-2
Age at entry Breast-cancer deaths Rate ratio (95% CI)*
(years)
Intervention Control Unadjusted Adjusted
n Rate/105 n Rate/105 SES-1 SES-2
Cohort 1
45–49 27 3·43 33 4·36 0·78 (0·46–1·32) 0·73 (0·43–1·24) 0·70 (0·41–1·20)
50–54 44 5·64 35 5·16 1·09 (0·69–1·71) 1·03 (0·65–1·63) 0·99 (0·62–1·58)
55–59 43 5·49 55 7·56 0·71 (0·47–1·07) 0·68 (0·45–1·03) 0·65 (0·43–0·99)
60–64 42 6·67 44 7·55 0·87 (0·57–1·35) 0·83 (0·54–1·29) 0·80 (0·51–1·25)
45–64 156 5·18 167 6·04 0·87 (0·70–1·06) 0·82 (0·65–1·05) 0·79 (0·60–1·02)
All cohorts
45–49 47 3·35 53 4·19 0·83 (0·54–1·27) 0·78 (0·50–1·21) 0·75 (0·48–1·18)
*Intervention group versus control group.
Table 3: Breast-cancer mortality during 14 years of follow-up
When general practices were grouped by SES-2 there
was a strong trend in the control group of mortality rates
in cohort 1 and a weaker trend in the intervention group
towards higher breast-cancer rates in those of higher
SES (table 4). The benefit of screening seems to be
concentrated in women of higher SES, but neither the
interactions with SES-2 nor those with Carstairs score
were significant.
Other-cause mortality rates were significantly lower in
the intervention group than in the control group (rate
ratio 0·84 [95% CI 0·79–0·90]) but after adjustment for
Carstairs score (the continuous variable) this difference
was no longer apparent (0·98 [0·92–1·04]).
In general, the results were not affected by censoring
by study year of diagnosis. When censoring was applied
to cases diagnosed after study year 10, the observed
benefit in the intervention group was 29% (rate ratio
0·71 [0·53–0·95] if deaths after diagnoses after study
year 10 are excluded). Figure 2 shows breast-cancer
mortality with this censoring applied. Results were
similar for the other censoring imposed for diagnosis
around 3–4 years after the end of the study (study years
9–12, calendar years 1990–92).
If deaths in the 45–49-year age-group were censored
according to age at diagnosis, no benefit in the
intervention group was observed when analyses were
restricted to deaths of women whose breast cancers were
diagnosed before they reached age 50 years (rate ratio
2·36 [0·79–7·08]); substantial benefit was seen when
these deaths were excluded (0·47 [0·25–0·89]). The
question of benefit from screening offered to women
before they reach age 50 years (in addition to that from
routine screening in their fifties) can be addressed, but
with limited power, by comparison of breast-cancer
mortality by trial group for younger women (entrants
45–46 years) in cohorts 2 and 3; for these women the
rate ratios were 0·83 and 0·50, respectively (with wide
95% CI, 0·32–2·18 and 0·11–2·23).
D i s c u s s i o n
This report of the Edinburgh randomised trial of breast-
cancer screening, with “before randomisation” consent
and no offer of screening to the control group, includes
nearly 70 000 woman-years of follow-up. Trials in
Canada included a volunteer population all of whom,
including the control group, received some form of
intervention at entry to the trial1 3 or throughout the
s t u d y .1 4 Because of recruitment of two later cohorts of
women aged 45–49 years, the Edinburgh trial provides a
substantial contribution to the total information
available on the screening of younger women (more than
2 70 000 woman-years of follow-up). A limitation of this
trial has been the imbalance between the intervention
and control groups for other-cause mortality rates. New
computer software has enabled us to access postal codes
for all women, so we have been able to derive an
improved estimate of general practice SES (SES-2).5
The variation in SES explains the difference in other-
cause mortality rates and thus allows best estimates of
effects on breast-cancer mortality.
Application of SES-2 gave an overall point estimate
for the difference between intervention and control
groups in breast-cancer mortality rates in the Edinburgh
trial at 14 years of follow-up as 21%; this estimate is of
borderline significance (rate ratio 0·79 [95% CI
0·60–1·02]). If SES-2 is applied to our previously
reported results at 10 years of follow-up, the difference
in breast-cancer mortality rates is 24%, compared with
the 18% first reported. This difference approaches
significance (rate ratio 0·76 [0·55–1·06]).5 T h e s e
benefits do show some variation by age, with the largest
benefits in women first screened in their late fifties and
none in those first screened in their early fifties.
Although this latter observation is consistent with results
from some other trials,1 5 we emphasise that the formal
test of heterogeneity by age-group did not approach
s i g n i f i c a n c e .
Breast cancers diagnosed after a suitable period from
the end of the study clearly cannot have been influenced
by trial screening, and the inclusion of deaths after these
later diagnoses dilutes the comparison by trial group. In
the HIP study, screening seemed to have no impact on
diagnoses 3·0–3·5 years after the end of the study.7 T h e
first comparisons of the Swedish overview, based on
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SES-2 Intervention Control Rate ratio†
n Rate/104 n Rate/104
(95% CI)
High 87 5·47 31 8·11 0·68 (0·44–1·03)
Medium 44 5·16 60 6·08 0·86 (0·58–1·27)
Low 25 4·39 76 5·45 0·78 (0·49–1·44)
*Breast cancer was the underlying cause of death. Rates are those per 10 000
woman-years at risk.
†Adjusted for age at survey entry, and, where appropriate, for cohort.
Table 4: Breast-cancer mortality by SES-2 in cohort 1 
(45–64 years)
Figure 2: Cumulative mortality from breast cancer (underlying
cause of death) for all women in cohort 1 and for women
aged 45–49 years at trial entry in all cohorts
*Deaths following diagnoses up to study year 10. 
short follow-up periods (mean 10 years) found only
slight differences between follow-up (without censoring)
and evaluation (with censoring) models, but later
comparisons have shown increased estimates of benefit
when censoring is imposed.1 6 We found that estimated
benefit was slightly larger when deaths from diagnoses
more than 3–4 years after the end of the study
w e r e censored, with no evidence for attenuation of
benefit at 14 years of follow-up. The HIP study7 d i d
show attenuation with, for example, deaths from
diagnoses up to study year 7 showing benefits of 34·7%,
29·3%, and 22·2% at 7 years, 10 years, and 14 years of
f o l l o w - u p .
In view of the controversy over age at which screening
should start, the results for women aged 45–49 years at
entry are particularly important. Since there is no
statistical evidence of heterogeneity between breast-
cancer mortality benefit and age at entry, there is no
reason to suppose that benefit is less for women first
screened under 50 years than for older women.
Furthermore, when age-specific results were derived, the
estimated difference in breast-cancer mortality rates for
those aged 45–49 years, although not significant by
itself, is no less than in older entrants. In addition, there
is no evidence that the benefit emerged later in these
younger women. The 25% difference in mortality rate at
14 years of follow-up in women aged 45–49 years at
entry agrees closely with most meta-analyses of
randomised trials.1 7
There are the two critical components to the decision
whether population screening for breast cancer should
be available to women younger than 50 years. First, do
women first screened when younger than 50 have lower
breast-cancer mortality than those not so screened; and
can the same benefit be achieved by screening from the
age of 50 years? Even after a US National Institutes of
Health consensus conference these issues remain
c o n t r o v e r s i a l .1 8 – 2 0 Although our numbers for such women
are small, the Edinburgh trial findings make an
important contribution to the first question.
The second question is more complex. Deaths
classified by age at diagnosis require careful
interpretation; for purposes of comparison with the HIP
t r i a l7 we have presented results for younger entrants to
the trial with diagnoses at 50 years or older and
diagnoses at less than 50 years censored. Our results
agree with those of the HIP trial that the benefit in
women entering the trial before the age of 50 years is
evident only in deaths occurring in their fifties and from
cancers diagnosed after age 50 years. These observations
could be artefacts with lead time advancing age at
diagnosis to under 50 years in some women in the
intervention group who, if unscreened, would have been
diagnosed in their fifties. A proportion of the benefit
(possibly 70%)2 1 will be attributable to screening of
women in their fifties. The design of the Edinburgh trial
means that its analyses, based on randomisation, can
address the second question for younger entrants to
cohorts 2 and 3 (since almost all trial screening was
done before age 50 years and women in both trial groups
were eligible for Forrest screening), but the numbers
available for analysis are small and the results equivocal.
An observational study2 2 on these cohorts and entrants at
ages 45–49 years and 50–52 years to the initial cohort of
the intervention group reported lower mortality rates for
women in their fifties screened under 50 years.
The improved method of analysis and longer follow-
up period have now shown a reduction of 21% in breast-
cancer mortality for women aged 45–64 years at entry to
the intervention group of the Edinburgh trial; this
difference is of borderline significance. Consideration of
the results at follow-up periods of 7 years and 10 years,
and 14 years follow-up censored by study year of
diagnosis indicates a benefit of 25–29% in a population
offered regular screening (the steady state). The
reduction is close to but smaller than the 30% expected
when available data were restricted to HIP trial, the
Swedish two-county trial, and case-control analyses of
s c r e e n i n g .2 3 Compared with the Swedish two-county
t r i a l2 4 pathological characteristics of cancers in screened
women in Edinburgh showed that screening in
Edinburgh (which used current mammographic
technology) has not advanced the diagnosis sufficiently
to influence histological grade despite reducing size and
frequency of node involvement.2 5 Although there is no
reason to believe this finding is not typical of the UK,
i t may explain why mortality benefit has not been larger.
Mammographic standards have certainly improved
s i n c e the Edinburgh study but our data come from a
research setting with a 2-year interval between
screening. These data may not be applicable without
reduction in benefit to screening done as part of routine
health service with a 3-year interval. Only cautious
optimism is appropriate. Subgroup analyses presented
here and by the Swedish investigators,1 5 and one
Swedish trial of younger women,2 6 are very promising
f o r women younger than 50 years when first screened,
but we believe that decisions on service screening in
t h i s age-group should await the results of specifically
designed randomised trials (UK Age Trial and
EUROTRIAL). 
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